Bottom line
PPH vs IHE: the short answer
PPH (VanEck Pharmaceutical ETF) and IHE (iShares U.S. Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 43% by weight.
But IHE is far broader, holding 59 positions to 26 for PPH, so beyond the top names it adds exposure PPH doesn't have.
PPH is cheaper at 0.36% vs 0.37% — a difference of $1.00 a year per $10,000 invested.
Over five years, PPH returned +11.3% a year vs +9.1% for IHE.
Updated Nov 19, 2026
PPH vs IHE side by side
| PPH | IHE | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | VanEck | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.36% | 0.37% |
| Annual cost per $10k | $36 | $37 |
| 10-yr cost on $10k (prospectus) | $456 | $468 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +21.9% | +31.7% |
| 5-yr return (annualized) | +11.3% | +9.1% |
| 10-yr return (annualized) | +6.7% | +6.2% |
| Best quarter | +16.5% | +17.6% |
| Worst quarter | −15.0% | −16.0% |
| Net assets (fund) | $879.5M | $1.1B |
| Number of holdings | 26 | 59 |
| Portfolio turnover | 3% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PPH | IHE | Difference |
|---|---|---|---|
| 2025 | +21.9% | +31.7% | −9.8% |
| 2024 | +8.1% | +8.1% | +0.1% |
| 2023 | +6.9% | +1.0% | +5.9% |
| 2022 | +2.6% | −4.8% | +7.4% |
| 2021 | +18.3% | +12.8% | +5.5% |
| 2020 | +5.2% | +13.8% | −8.6% |
| 2019 | +19.1% | +15.5% | +3.6% |
| 2018 | −5.7% | −7.7% | +2.0% |
| 2017 | +15.4% | +10.7% | +4.7% |
| 2016 | −17.8% | −11.7% | −6.0% |
Source: Fund prospectus bar charts
Holdings overlap
11 of PPH's top 25 holdings also appear in IHE's top 25.
| Holding | PPH | IHE |
|---|---|---|
| Eli Lilly & Co | 20.23% | 22.25% |
| Merck & Co Inc | 9.85% | 4.55% |
| Pfizer Inc | 4.51% | 3.96% |
| Bristol-Myers Squibb Co | 4.47% | 4.37% |
| Johnson & Johnson | 4.35% | 22.44% |
| Zoetis Inc | 2.10% | 3.73% |
| Viatris Inc | 1.10% | 4.22% |
| Axsome Therapeutics Inc | 0.77% | 2.42% |
| Corcept Therapeutics Inc | 0.50% | 1.90% |
| Elanco Animal Health Inc | 0.35% | 2.81% |
| Organon & Co | 0.23% | 0.81% |
Source: SEC Form N-PORT
PPH top 10
- Eli Lilly & Co — 20.23%
- Novartis AG — 10.63%
- Merck & Co Inc — 9.85%
- Novo Nordisk A/S — 5.37%
- AbbVie Inc — 4.57%
- Pfizer Inc — 4.51%
- Bristol-Myers Squibb Co — 4.47%
- Gsk Plc — 4.42%
- Johnson & Johnson — 4.35%
- AstraZeneca PLC — 4.33%
IHE top 10
- Johnson & Johnson — 22.44%
- Eli Lilly And Company — 22.25%
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 6.24%
- Merck & Co., Inc. — 4.55%
- Bristol-myers Squibb Company — 4.37%
- Royalty Pharma Plc — 4.34%
- Viatris Inc. — 4.22%
- Pfizer Inc. — 3.96%
- Zoetis Inc. — 3.73%
- Jazz Pharmaceuticals Public Limited Company — 3.45%
FAQ
What is the difference between PPH and IHE?
Which is cheaper, PPH or IHE?
Should I own both PPH and IHE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.